To support countries in the European Union/European Economic Area (EU/EEA) in their review of preparedness system planning, ECDC launches an operational checklist for health emergency preparedness for imported cases of high consequence infectious diseases.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 19-26 October 2019 and includes updates on chikungunya, dengue, eastern equine encephalitis, Ebola virus, influenza, mass gathering monitoring in Japan.
This estimate on the “PrEP gap” in Europe was published in a paper in Eurosurveillance stating that 500 000 men who have sex with men in the European Union currently cannot access HIV pre-exposure prophylaxis (PrEP), despite being very likely to use it.
This report summarises key issues related to HIV and people who inject drugs in Europe and Central Asia based on data provided by countries for reporting on the Dublin Declaration in 2018.
The ECDC Communicable Disease Threats Report (CDTR) is a weekly bulletin for epidemiologists and health professionals on active public health threats. This issue covers the period 8-14 September 2019 and includes updates on Ebola virus disease, dengue, chikungunya, Vibrio growth in the Baltic Sea, and West Nile virus.
The ECDC Communicable Disease Threats Report (CDTR) is a weekly bulletin for epidemiologists and health professionals on active public health threats. This issue covers the period from 14-24 August 2019 and includes updates on Ebola virus disease in the Democratic Republic of the Congo, monitoring environmental sustainability of Vibrio growth in the Baltic Sea, West Nile virus infection, haemorrhagic fever with renal syndrome in Croatia and Slovenia, the mass gathering of the Hajj in Saudi Arabia and Listeriosis in Spain. (Erratum (26 August 2019): On pages 2 and 5 (West Nile virus infection), the figure of eight deaths in Greece (4), Cyprus (1) and Serbia (1) has been amended to four deaths in Greece (2), Cyprus (1) and Serbia (1)
Two out of the four drugs tested in a multi-drug randomised control trial have been found more effective in treating Ebola, the World Health Organization announced on Monday. The Data and Safety Monitoring Board, an independent body that has been reviewing interim safety and efficacy data, has therefore recommended that the study be stopped and that all future patients be randomized to receive either REGN-EB3 or mAb114, in what is being considered an extension phase of the study.